Survodutide for Obesity: Systematic Review of the GLP-1/Glucagon Dual Agonist

Systematic review of survodutide efficacy and safety for obesity consolidates evidence for this dual GLP-1/glucagon agonist approaching clinical use.

Awad, Abdelaziz A et al.·Proceedings (Baylor University. Medical Center)·2025·
RPEP-100232025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

Systematic review of survodutide efficacy and safety for obesity consolidates evidence for this dual GLP-1/glucagon agonist approaching clinical use.

Key Numbers

How They Did This

In publication.

Why This Research Matters

Relevant to peptide therapeutics.

The Bigger Picture

Advances peptide evidence.

What This Study Doesn't Tell Us

In publication.

Questions This Raises

  • ?Long-term implications?
  • ?Evidence comparison?
  • ?Next steps?

Trust & Context

Key Stat:
Key finding Systematic review of survodutide efficacy and safety for obesity consolidates evidence for this dual
Evidence Grade:
Based on design.
Study Age:
Published in 2025.
Original Title:
Evaluating the efficacy and safety of survodutide for obesity: a systematic review and meta-analysis of randomized controlled trials.
Published In:
Proceedings (Baylor University. Medical Center), 38(4), 514-522 (2025)
Database ID:
RPEP-10023

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

What does this mean?

Systematic review of survodutide efficacy and safety for obesity consolidates evidence for this dual GLP-1/glucagon agonist approaching clinical use.

How reliable?

Consult publication.

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-10023·https://rethinkpeptides.com/research/RPEP-10023

APA

Awad, Abdelaziz A; Abdrabou Abouelmagd, Alaa; Mohammed, Fatma; Elettreby, Abdelrahman M; Mahmoud Marey, Mohamed; Aldemerdash, Mohamed A; Soliman, Samar M; Belal, Mohamed Mohamed; Abosheaishaa, Hazem. (2025). Evaluating the efficacy and safety of survodutide for obesity: a systematic review and meta-analysis of randomized controlled trials.. Proceedings (Baylor University. Medical Center), 38(4), 514-522. https://doi.org/10.1080/08998280.2025.2480512

MLA

Awad, Abdelaziz A, et al. "Evaluating the efficacy and safety of survodutide for obesity: a systematic review and meta-analysis of randomized controlled trials.." Proceedings (Baylor University. Medical Center), 2025. https://doi.org/10.1080/08998280.2025.2480512

RethinkPeptides

RethinkPeptides Research Database. "Evaluating the efficacy and safety of survodutide for obesit..." RPEP-10023. Retrieved from https://rethinkpeptides.com/research/awad-2025-evaluating-the-efficacy-and

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.